Prevalence of secondary erythrocytosis in men receiving testosterone therapy

Autor: Rohit Reddy, Parris Diaz, Ruben Blachman-Braun, Justin Loloi, Farah Rahman, Jesse Ory, Alexandra Dullea, Isaac Zucker, Daniel C. Gonzalez, Eliyahu Kresch, Ranjith Ramasamy
Rok vydání: 2023
Předmět:
Zdroj: Canadian Urological Association Journal. 17
ISSN: 1920-1214
1911-6470
DOI: 10.5489/cuaj.8210
Popis: Introduction: Increased hematocrit (HCT) is a common adverse effect in men on testosterone therapy (TTh). We aimed to uncover differences in HCT changes among men receiving different forms of TTh, namely intranasal gels, intramuscular injections, and subcutaneous pellets. Methods: We conducted a single-center, retrospective, matched-cohort study of patients treated for testosterone deficiency (TD) to investigate the effect of three TTh regimens on HCT. We included men who received intranasal testosterone (NT), intramuscular testosterone (TC), or subcutaneous testosterone pellet (TP) regimens between January 2011 and December 2020. We matched treatment cohorts 1:1:1 for age, body mass index (BMI), and history of obstructive sleep apnea. Those taking TTh for less than 16 weeks were excluded. Comparison between groups was performed with U-Mann Whitney test, Student t-test, ANOVA, or Kruskal Wallis test as appropriate. Results: Seventy-eight matched-cohort individuals with testosterone deficiency (TD) received either NT, TC, or TP. The most common TD symptoms prior to initiation of TTh were erectile dysfunction (38%), low libido (22%), and lack of energy (17%). Baseline serum testosterone and HCT were higher in NT (p
Databáze: OpenAIRE
Externí odkaz: